Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-Paclitaxel vs Paclitaxel with Carboplatin in Neoadjuvant TNBC
NCT04067102Withdrawn
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- May 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of paclitaxel in triple-negative breast cancer (TNBC) (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: pathologic complete response at 6 months. Planned start May 2019; status: withdrawn.
02
Drugs
paclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04067102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04067102.